WO2006033756A3 - Multiple rna polymerase iii promoter expression constructs - Google Patents

Multiple rna polymerase iii promoter expression constructs Download PDF

Info

Publication number
WO2006033756A3
WO2006033756A3 PCT/US2005/029976 US2005029976W WO2006033756A3 WO 2006033756 A3 WO2006033756 A3 WO 2006033756A3 US 2005029976 W US2005029976 W US 2005029976W WO 2006033756 A3 WO2006033756 A3 WO 2006033756A3
Authority
WO
WIPO (PCT)
Prior art keywords
polymerase iii
expression constructs
rna polymerase
iii promoter
promoter expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/029976
Other languages
French (fr)
Other versions
WO2006033756A2 (en
Inventor
Catherine J Pachuk
Daniel E Mccallus
Chandrasekhar Satishchandran
Martin D Sigg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nucleonics Inc
Original Assignee
Nucleonics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA002577519A priority Critical patent/CA2577519A1/en
Application filed by Nucleonics Inc filed Critical Nucleonics Inc
Priority to JP2007530052A priority patent/JP4804467B2/en
Priority to EP05810305A priority patent/EP1784492B1/en
Priority to US11/660,937 priority patent/US7985581B2/en
Priority to CN2005800362406A priority patent/CN101189343B/en
Priority to AU2005287365A priority patent/AU2005287365B2/en
Priority to AT05810305T priority patent/ATE483815T1/en
Priority to DE602005024015T priority patent/DE602005024015D1/en
Publication of WO2006033756A2 publication Critical patent/WO2006033756A2/en
Publication of WO2006033756A3 publication Critical patent/WO2006033756A3/en
Anticipated expiration legal-status Critical
Priority to US13/160,774 priority patent/US20120028348A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Expression constructs comprising at least two different RNA polymerase III promoters, wherein each promoter is operably linked to a nucleic acid sequence encoding an RNA effector molecule, are disclosed herein. Further provided are expression constructs comprising multiple polymerase III promoters operably linked to sequences encoding short hairpin RNA molecules, which may comprise single and/or multiple fingers. The provided constructs are useful for in vivo delivery of RNA molecules effective in gene silencing, including of viral genes including HBV and HCV.
PCT/US2005/029976 2004-08-23 2005-08-23 Multiple rna polymerase iii promoter expression constructs Ceased WO2006033756A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DE602005024015T DE602005024015D1 (en) 2004-08-23 2005-08-23 EXPRESSION CONSTRUCTS WITH SEVERAL RNA POLYMERASE III PROMOTERS
JP2007530052A JP4804467B2 (en) 2004-08-23 2005-08-23 Multiple RNA polymerase III promoter expression construct
EP05810305A EP1784492B1 (en) 2004-08-23 2005-08-23 Multiple rna polymerase iii promoter expression constructs
US11/660,937 US7985581B2 (en) 2004-08-23 2005-08-23 Multiple RNA polymerase III promoter expression constructs
CN2005800362406A CN101189343B (en) 2004-08-23 2005-08-23 Multiple rna polymerase iii promoter expression constructs
CA002577519A CA2577519A1 (en) 2004-08-23 2005-08-23 Multiple rna polymerase iii promoter expression constructs
AT05810305T ATE483815T1 (en) 2004-08-23 2005-08-23 EXPRESSION CONSTRUCTS WITH MULTIPLE RNA POLYMERASE III PROMOTERS
AU2005287365A AU2005287365B2 (en) 2004-08-23 2005-08-23 Multiple RNA polymerase III promoter expression constructs
US13/160,774 US20120028348A1 (en) 2004-08-23 2011-06-15 Multiple rna polymerase iii promoter expression constructs

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60362204P 2004-08-23 2004-08-23
US60/603,622 2004-08-23
US62994204P 2004-11-22 2004-11-22
US60/629,942 2004-11-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/160,774 Continuation US20120028348A1 (en) 2004-08-23 2011-06-15 Multiple rna polymerase iii promoter expression constructs

Publications (2)

Publication Number Publication Date
WO2006033756A2 WO2006033756A2 (en) 2006-03-30
WO2006033756A3 true WO2006033756A3 (en) 2007-01-18

Family

ID=36090440

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/029976 Ceased WO2006033756A2 (en) 2004-08-23 2005-08-23 Multiple rna polymerase iii promoter expression constructs

Country Status (8)

Country Link
US (2) US7985581B2 (en)
EP (3) EP2270161A3 (en)
JP (1) JP4804467B2 (en)
AT (1) ATE483815T1 (en)
AU (1) AU2005287365B2 (en)
CA (1) CA2577519A1 (en)
DE (1) DE602005024015D1 (en)
WO (1) WO2006033756A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8575327B2 (en) 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
EP2270162B1 (en) * 2003-06-12 2018-10-03 Alnylam Pharmaceuticals Inc. Conserved hbv and hcv sequences useful for gene silencing
AU2016202897A1 (en) * 2004-12-22 2016-05-19 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
EP2316942B1 (en) * 2004-12-22 2021-04-21 Alnylam Pharmaceuticals, Inc. Conserved hbv and hcv sequences useful for gene silencing
JP2008237023A (en) * 2005-07-15 2008-10-09 Univ Of Tokyo Multiple shRNA expression vector
WO2008147430A2 (en) * 2006-10-11 2008-12-04 Nucleonics, Inc. Microrna-formatted multitarget interfering rna vector constructs and methods of using the same
DK2548438T3 (en) 2006-11-08 2015-10-19 Veritas Bio LLC IN VIVO SUBMITTING DOUBLE-STRENGTH RNA TO A CELL
WO2008148068A1 (en) * 2007-05-23 2008-12-04 Mannkind Corporation Multicistronic vectors and methods for their design
US9029341B2 (en) * 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
US20140275211A1 (en) 2011-06-21 2014-09-18 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
US20130064881A1 (en) * 2011-09-08 2013-03-14 Gradalis, Inc. Compositions and methods for treating prostate cancer
WO2013067050A1 (en) 2011-10-31 2013-05-10 University Of Utah Research Foundation Genetic alterations in glioblastoma
CN104394892B (en) * 2012-05-15 2020-02-14 北京命码生科科技有限公司 Plant as functional microRNA and/or functional siRNA carrier, preparation method and application thereof
WO2015048690A1 (en) 2013-09-27 2015-04-02 The Regents Of The University Of California Optimized small guide rnas and methods of use
US11339437B2 (en) * 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
ES2745769T3 (en) 2014-03-10 2020-03-03 Editas Medicine Inc CRISPR / CAS related procedures and compositions for treating Leber 10 congenital amaurosis (LCA10)
WO2016030863A1 (en) 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
WO2016073559A1 (en) * 2014-11-05 2016-05-12 The Regents Of The University Of California Methods for autocatalytic genome editing and neutralizing autocatalytic genome editing
KR102545316B1 (en) 2014-11-10 2023-06-22 알닐람 파마슈티칼스 인코포레이티드 Hepatitis b virus (hbv) irna compositions and methods of use thereof
US11267842B2 (en) 2015-03-03 2022-03-08 The Regents Of The University Of California Enzymatic modification of nucleic acids
TWI554608B (en) * 2015-03-27 2016-10-21 Univ China Medical A nucleic acid sequence segment for enhancing protein expression, an expression vector comprising a sequence segment thereof, and a kit comprising its expression vector
WO2017177029A1 (en) * 2016-04-06 2017-10-12 Duke University Compositions and methods for enhanced gene expression and viral replication
BR112019001887A2 (en) 2016-08-02 2019-07-09 Editas Medicine Inc compositions and methods for treating cep290-associated disease
EP3496727A4 (en) * 2016-08-12 2020-03-18 The Regents of the University of California CONSTRUCTIONS AND METHOD FOR SIGNAL ENHANCEMENT
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
NZ762100A (en) 2017-08-09 2025-12-19 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof
DK3768846T5 (en) * 2018-03-21 2024-08-19 Aldevron L L C VIRAL AND NON-VIRAL NANOPLASMID VECTORS WITH ENHANCED PRODUCTION
EP3833766A1 (en) * 2018-08-09 2021-06-16 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
JP7625512B2 (en) 2018-08-13 2025-02-03 アルナイラム ファーマシューティカルズ， インコーポレイテッド Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof
US20220195428A1 (en) * 2019-01-29 2022-06-23 The Genera Hospital Corporation Oligonucleotides and methods for the treatment of age-related macular degeneration
CN114277030B (en) * 2021-12-28 2024-07-16 滨州医学院 A pri-miRNA improved sequence and a vector expressing the sequence

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035718A2 (en) * 2003-10-03 2005-04-21 Welgen, Inc. Biderectional promoters for small rna expression
WO2005111219A1 (en) * 2004-04-16 2005-11-24 University Of Washington METHODS AND VECTORS FOR EXPRESSING siRNA

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643771A (en) 1980-05-19 1997-07-01 The Board Of Trustees Of The Leland Stanford Junior University Non-reverting live bacterial vaccines
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5547862A (en) 1993-07-29 1996-08-20 Ambion Inc. Vectors containing multiple promoters in the same orientation
US5624803A (en) 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
EP0728202A4 (en) 1993-11-12 1997-04-23 Univ Case Western Reserve Episomal expression vector for human gene therapy
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5585263A (en) 1994-05-20 1996-12-17 University Of Alabama At Birmingham Research Foundation Purified retroviral constitutive transport enhancer and its use to facilitate mRNA transport, and to produce recombinant, attenuated HIV
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5877159A (en) 1995-05-03 1999-03-02 University Of Maryland At Baltimore Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
US5932241A (en) 1995-06-07 1999-08-03 Valentis, Incorporated Cationic lipid DNA complexes for gene targeting
US5824538A (en) 1995-09-06 1998-10-20 The United States Of America As Represented By The Secretary Of The Army Shigella vector for delivering DNA to a mammalian cell
AU7450496A (en) 1995-10-20 1997-05-07 Collagen Corporation Production of recombinant procollagen in yeast
US5851804A (en) 1996-05-06 1998-12-22 Apollon, Inc. Chimeric kanamycin resistance gene
KR20000068934A (en) 1996-11-08 2000-11-25 스티븐 로쓰 Improved Expression Vectors
US5874242A (en) 1997-03-19 1999-02-23 University Of Georgia Research Foundation, Inc. Efficient translation in eukaryotic and prokaryotic systems
AU745805B2 (en) 1997-10-28 2002-04-11 Wyeth Compositions and methods for delivery of genetic material
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
KR20010041902A (en) 1998-03-16 2001-05-25 데이비드 엠 모이어 Method of reducing cellulite in mammalian skin
KR20070118315A (en) 1999-04-21 2007-12-14 와이어쓰 Compositions for Inhibiting the Function of Polynucleotide Sequences
CA2369944A1 (en) 2001-01-31 2002-07-31 Nucleonics Inc. Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
JP2003269028A (en) 2002-03-18 2003-09-25 Aisin Seiki Co Ltd Door unlocking device
CA2487274A1 (en) 2002-05-06 2003-11-13 Nucleonics Inc. Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
EP1540004A4 (en) 2002-07-31 2007-10-03 Nucleonics Inc Double stranded rna structures and constructs, and methods for generating and using the same
US7303906B2 (en) 2002-09-06 2007-12-04 Wisconsin Alumni Research Foundation Competent bacteria
CA2502649A1 (en) 2002-10-18 2004-04-29 Nucleonics Inc. Double-stranded rna structures and constructs, and methods for generating and using the same
ATE554185T1 (en) 2003-02-27 2012-05-15 Alnylam Pharmaceuticals Inc METHODS AND CONSTRUCTS FOR EVALUATION OF RNAI TARGETS AND EFFECTOR MOLECULES
EP2270162B1 (en) 2003-06-12 2018-10-03 Alnylam Pharmaceuticals Inc. Conserved hbv and hcv sequences useful for gene silencing
WO2005007875A2 (en) 2003-07-18 2005-01-27 University Of Massachusetts Enhanced promoters for synthesis of small hairpin rna
WO2005007877A2 (en) 2003-07-18 2005-01-27 University Of Massachusetts Regulatable promoters for synthesis of small hairpin rna
WO2005040388A2 (en) 2003-08-22 2005-05-06 Nucleonics Inc. Eukariotic expression systems for expression of inhibitory rna in multiple intracellular compartments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005035718A2 (en) * 2003-10-03 2005-04-21 Welgen, Inc. Biderectional promoters for small rna expression
WO2005111219A1 (en) * 2004-04-16 2005-11-24 University Of Washington METHODS AND VECTORS FOR EXPRESSING siRNA

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BODEN D. ET AL.: "Promoter choice affects the potency of HIV-1 specific RNA interference", NUCLEIC ACIDS RESEARCH, vol. 31, no. 7, 2003, pages 5033 - 5038, XP002383800 *
CZAUDERNA F. ET AL.: "Inducible shRNA expression for application in a prostate cancer mouse model", NUCLEIC ACIDS RESEARCH, vol. 31, no. 21, 2003, pages E127, XP002341775 *
DATABASE EMBL-EBI 20 May 1992 (1992-05-20), MURPHY S. ET AL.: "7SK RNA; Alu repetitive sequence; small cytoplasmic RNA", XP002404574, Database accession no. X04992 *
GILADI H. ET AL.: "Small interfering RNA inhibits Hepatitis B virus replication in mice", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA,, US, vol. 8, no. 5, November 2003 (2003-11-01), pages 769 - 776, XP008040415, ISSN: 1525-0016 *
KRÖNKE J. ET AL.: "Alternative approaches for efficient inhibition of Hepatitis C virus RNA replication by small interfering RNAs", JOURNAL OF VIROLOGY, vol. 78, no. 7, April 2004 (2004-04-01), pages 3436 - 3446, XP002300966 *
LI M.-J. ET AL.: "Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs", MOLECULAR THERAPY, vol. 8, no. 2, August 2003 (2003-08-01), pages 196 - 206, XP002982612 *
MCCAFFREY A.P. ET AL.: "Inhibition of hepatitis B virus in mice by RNA interference", NATURE BIOTECHNOLOGY, vol. 21, no. 6, June 2003 (2003-06-01), pages 639 - 644, XP002311189 *
MURPHY S. ET AL.: "A sequence upstream from the coding region is required for the transcription of the 7SK RNA genes", NUCLEIC ACIDS RESEARCH, vol. 14, no. 23, 1986, pages 9243 - 9260, XP002383798 *
PEBERNARD S. AND IGGO R.D.: "Determinants of interferon-stimulated gene induction by RNAi vectors", DIFFERENTIATION, vol. 72, March 2004 (2004-03-01), pages 103 - 111, XP002383799 *
TALLET-LOPEZ B. ET AL.: "Antisense oligonucleotides targeted to the domain IIId of the hepatitis C virus IRES compete with 40S ribosomal subunit binding and prevent in vitro translation", NUCLEIC ACIDS RESEARCH, vol. 31, no. 2, 2003, pages 734 - 742, XP002383801 *
YING CHEN ET AL.: "Inhibition of hepatitis B virus replication by stably expressed shRNA", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 311, 2003, pages 398 - 404, XP004468647 *

Also Published As

Publication number Publication date
US20090298909A1 (en) 2009-12-03
JP2008510489A (en) 2008-04-10
US20120028348A1 (en) 2012-02-02
EP1784492A2 (en) 2007-05-16
EP2270161A2 (en) 2011-01-05
EP2270161A3 (en) 2011-02-02
DE602005024015D1 (en) 2010-11-18
EP2169072A1 (en) 2010-03-31
AU2005287365B2 (en) 2011-02-10
WO2006033756A2 (en) 2006-03-30
AU2005287365A1 (en) 2006-03-30
JP4804467B2 (en) 2011-11-02
CA2577519A1 (en) 2006-03-30
US7985581B2 (en) 2011-07-26
EP1784492B1 (en) 2010-10-06
ATE483815T1 (en) 2010-10-15

Similar Documents

Publication Publication Date Title
WO2006033756A3 (en) Multiple rna polymerase iii promoter expression constructs
JP6752957B2 (en) A novel process for the production of oligonucleotides
WO2004015075A3 (en) SHORT INTERFERING RNAs HAVING A HAIRPIN STRUCTURE CONTAINING A NON-NUCLEOTIDE LOOP
EP2434020A3 (en) Method of producing minus strand RNA virus vector with the use of hybrid promoter containing cytomegalovirus enhancer and avian beta-actin promoter
JP2005517427A5 (en)
WO2011056005A3 (en) Novel sirna structure for minimizing off-target effects caused by antisense strands, and use thereof
JP2006502694A5 (en)
WO2003057840A3 (en) Compositions for dna mediated gene silencing
JP2015142558A5 (en)
JP2017093448A5 (en)
NZ599237A (en) Sirna compounds comprising terminal substitutions
JP2014527401A5 (en)
WO2005121372A3 (en) Double strand compositions comprising differentially modified strands for use in gene modulation
CA2457528A1 (en) Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina)
WO2010090857A3 (en) Methods for amplifying hepatitis c virus nucleic acids
RU2017130143A (en) CRISPR HYBRID DNA / RNA POLINUKDEOTOIDES AND METHODS
JP2005517432A5 (en)
WO2012092569A3 (en) Compositions comprising immunostimulatory nucleic acids and related methods
JP2015529469A5 (en)
WO2009073629A3 (en) Efficient shotgun sequencing methods
JP2014514921A5 (en)
WO2003051901A3 (en) Pseudonucleotide comprising an intercalator
WO2006041290A3 (en) Nucleic acids against viruses , in particular hiv
WO2006053683A3 (en) Gene silencing using sense dna and antisense rna hybrid constructs coupled to peptides facilitating the uptake into cells
WO2004044134A3 (en) Phosphorous-linked oligomeric compounds and their use in gene modulation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200580036240.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2577519

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007530052

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005287365

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005810305

Country of ref document: EP

Ref document number: 857/KOLNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005287365

Country of ref document: AU

Date of ref document: 20050823

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005287365

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005810305

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11660937

Country of ref document: US

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)